DISODIUM FOLINATE
Sponsors
Bristol Myers Squibb International Corporation, Bristol-Myers Squibb Services Unlimited Company, Charite Universitaetsmedizin Berlin KöR
Conditions
Colon cancer staged T3-4 and/or nodal positive by CT and/or MRI scan without distant metastases.Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient
Metastatic Colorectal Cancer (dMMR)Pan tumormetastatic colorectal cancer
Phase 2
Phase 3
CA209-8HW A Phase 3 Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or Investigator’s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer
Active, not recruitingCTIS2023-503956-29-00
Start: 2019-08-26Target: 571Updated: 2025-12-15
Post-resection/ ablation chemotherapy in patients with metastatic colorectal cancer (FIRE-9 - PORT / AIO-KRK-0418).
Prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of active post-resection/ ablation therapy in patients with metastatic colorectal cancer.
RecruitingCTIS2024-512174-10-00
Start: 2021-11-11Target: 507Updated: 2025-09-04
Pre-Operative Treatment in rEseCTable cOlon canceR (PROTECTOR/FIRE-10; AIO-KRK-0620; IAG-VO-0323)
Prospective, randomized, open-label, multicenter Phase III trial to investigate the efficacy of preoperative systemic therapy in advanced colon cancer
RecruitingCTIS2023-508076-11-00
Start: 2025-04-01Target: 714Updated: 2025-10-21